Consideration of differences in inhibitor potency between the different cell lines used in our study (Flt3-ITD+ AML cells such as MV4-11 vs. TF-1/Flt3-ITD cells) provides some additional mechanistic insight regarding inhibitor target kinase selection. The gene discussed is FLT3; the disease is acute myeloid leukemia.